Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotoxins for central nervous system malignancy

R J Youle1

  • 1Biochemistry Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1414, USA.

Seminars in Cancer Biology
|April 1, 1996
PubMed
Summary

New immunotoxins show promise for treating brain cancers. By linking tumor-targeting molecules to toxins, these agents offer specific cancer cell killing for primary brain tumors, metastatic brain tumors, and leptomeningeal carcinomatosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The C-terminal helix of Bcl-x(L) mediates Bax retrotranslocation from the mitochondria.

Cell death and differentiation·2012
Same author

Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1's inhibitory effect on Bak.

Oncogene·2011
Same author

Letter to the Editor: Sequence-specific 1H, 13C and 15N resonance assignments of recombinant onconase/P-30 protein.

Journal of biomolecular NMR·2010
Same author

Bcl-2 family interaction with the mitochondrial morphogenesis machinery.

Cell death and differentiation·2010
Same author

Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes.

Cell death and differentiation·2009
Same author

Which came first, the cytochrome c release or the mitochondrial fission?

Cell death and differentiation·2006

Area of Science:

  • Oncology
  • Neuroscience
  • Biotechnology

Background:

  • Current therapies for primary brain tumors, metastatic brain tumors, and leptomeningeal carcinomatosis are insufficient.
  • Monoclonal antibodies and biological ligands show tumor selectivity but lack therapeutic efficacy.
  • Immunotoxins, combining binding moieties with protein toxins, offer targeted cancer cell toxicity.

Purpose of the Study:

  • To review the development of novel immunotoxins for treating central nervous system (CNS) cancers.
  • To explore the potential of immunotoxins in managing challenging brain tumor conditions.

Main Methods:

  • Development of novel immunotoxin constructs by linking tumor-specific binding agents (e.g., monoclonal antibodies, transferrin, epidermal growth factor) to potent protein toxins.

Related Experiment Videos

  • Evaluation of immunotoxin efficacy and specificity in vitro and in preclinical models of CNS cancers.
  • Assessment of different administration routes, including systemic, intrathecal, and intratumoral injection.

    • Main Results:

    • Immunotoxins demonstrated significant cell-type specific toxicity against cancer cells in vitro.
    • The targeted delivery of toxins via immunotoxins offers a potential strategy for CNS cancer treatment.
    • Successful development of immunotoxins for potential application in various brain tumor types.

    Conclusions:

    • Immunotoxins represent a promising therapeutic strategy for primary brain tumors, metastatic brain tumors, and leptomeningeal carcinomatosis.
    • Targeted delivery of potent toxins via immunotoxins could overcome limitations of current inadequate therapies for CNS cancers.
    • Further development and clinical investigation of immunotoxins are warranted for effective brain cancer treatment.